AMRI extends API supply agreement with Shire

Adds another five-year term to the collaboration

AMRI has signed a multi-year supply agreement for an undisclosed product with Shire US Manufacturing, whose parent company, Shire, is focused on behavioural health, gastro intestinal diseases, rare diseases and regenerative medicine.

The collaboration extends a previously existing agreement between the two companies by five years. Financial terms have not been revealed.

‘We are pleased to extend this agreement with Shire,’ said Thomas D’Ambra, chairman, president and chief executive of AMRI. ‘Our partnership lays the groundwork for AMRI to be considered by Shire for future development and manufacturing opportunities.’